Orgaran
Extending the Frontiers of Venous Thrombosis Prophylaxis. "Haemostasis" Vol 22, No 2 (1992). Special Topic Issue: Pathophysiology of Haemostasis and Thrombosis 1992, Vol. 22, No. 2
Published on 10. June 1992
Book
Paperback/Softback
60 pages
978-3-8055-5626-2 (ISBN)
Description
Orgaran, composed of heparan, dermatan and chondroitin sulfates, is a new antithrombotic agent which shows great therapeutic potential. This proceedings issue discusses Orgaran's pharmacological mechanisms and presents pre-clinical trials as well as clinical trials in patients with heparin-induced thrombocytopenia and patients having hip surgery. In these studies, Orgaran is compared to either placebo or standard low-dose heparin. Results indicate that Orgaran has a particularly long biological half-life and produces less bleeding than heparin or an equivalent anti-thrombotic effect.
More details
Language
English
Place of publication
Basel
Switzerland
Target group
College/higher education
Professional and scholarly
Illustrations
13 Schaubilder, 28 Tabellen
13 figs., 28 tab.
Dimensions
Height: 25.2 cm
Width: 17.7 cm
Weight
170 gr
ISBN-13
978-3-8055-5626-2 (9783805556262)
Schweitzer Classification
Content
Orgaran (Org 10172) - its pharmacological profile in experimental models, D.G. Meuleman; anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849), F.A. Ofosu; pharmacokinetic considerations on Orgaran (Org 10172) therapy, M. Danhof, et al; Orgaran in heparin-induced thrombocytopenia, G.H. Chong and H.N. Magnani; Orgaran in the prevention of deep vein thrombosis in stroke patients, A.G.G. Turpie; studies of Org 10172 in patients with acute ischemic stroke, H.P. Adams, et al; Orgaran in hip fracture surgery, D. Bergqvist; prevention of deep vein thrombosis following total hip replacement surgery by Orgaran, J.W. ten Cate.